Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) Director Michael Houghton bought 3,202 shares of the company's stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average cost of $15.61 per share, for a total transaction of $49,983.22. Following the transaction, the director now owns 3,202 shares in the company, valued at $49,983.22. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Assembly Biosciences Price Performance
Shares of NASDAQ ASMB opened at $15.78 on Wednesday. Assembly Biosciences, Inc. has a 52 week low of $9.12 and a 52 week high of $19.93. The stock has a 50 day moving average price of $16.02 and a 200 day moving average price of $15.60.
Analysts Set New Price Targets
A number of analysts have recently commented on ASMB shares. Jefferies Financial Group raised shares of Assembly Biosciences from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $2.00 to $35.00 in a research report on Friday, September 20th. HC Wainwright reissued a "neutral" rating on shares of Assembly Biosciences in a research report on Friday, December 27th.
Apple feeling the heat from Nvidia
From Weiss Ratings | Ad
Nvidia has moved on to the next frontier of AI it intends to dominate.
And we believe the three companies partnering with Nvidia during this next stage of its AI supremacy are likely to benefit as well.
Learn more about Nvidia’s “Silent Partners” today.
Get Our Latest Analysis on Assembly Biosciences
Hedge Funds Weigh In On Assembly Biosciences
Hedge funds and other institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC lifted its stake in Assembly Biosciences by 131.0% in the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company's stock valued at $184,000 after acquiring an additional 7,690 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Assembly Biosciences by 39.2% during the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company's stock worth $753,000 after purchasing an additional 15,451 shares during the last quarter. Armistice Capital LLC bought a new stake in shares of Assembly Biosciences in the 2nd quarter valued at about $6,421,000. FMR LLC lifted its stake in Assembly Biosciences by 29.7% in the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company's stock valued at $240,000 after purchasing an additional 3,635 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Assembly Biosciences by 5,137.3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 3,442 shares during the period. 19.92% of the stock is owned by institutional investors.
About Assembly Biosciences
(
Get Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
